The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large‐scale cohort study in China
Background Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large‐scale Chinese cohort. Metho...
Saved in:
| Published in | Cancer Communications Vol. 42; no. 5; pp. 435 - 446 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley
01.05.2022
John Wiley & Sons, Inc John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large‐scale Chinese cohort.
Methods
A total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed‐up for 38,726.55 patient‐years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs.
Results
Four hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non‐Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non‐Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers.
Conclusion
Patients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. |
|---|---|
| AbstractList | BackgroundCancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large‐scale Chinese cohort.MethodsA total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed‐up for 38,726.55 patient‐years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs.ResultsFour hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non‐Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non‐Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers.ConclusionPatients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. Cancer incidence and mortality have received critical attention during the long-term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large-scale Chinese cohort. A total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed-up for 38,726.55 patient-years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs. Four hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non-Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non-Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers. Patients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. Background Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large‐scale Chinese cohort. Methods A total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed‐up for 38,726.55 patient‐years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs. Results Four hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non‐Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non‐Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers. Conclusion Patients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. Cancer incidence and mortality have received critical attention during the long-term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large-scale Chinese cohort.BACKGROUNDCancer incidence and mortality have received critical attention during the long-term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large-scale Chinese cohort.A total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed-up for 38,726.55 patient-years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs.METHODSA total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed-up for 38,726.55 patient-years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs.Four hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non-Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non-Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers.RESULTSFour hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non-Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non-Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers.Patients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity.CONCLUSIONPatients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. Abstract Background Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases (AIDs). This study aimed to investigate and compare the risk of cancer associated with five major AIDs in a large‐scale Chinese cohort. Methods A total of 8,120 AID patients consecutively admitted to a national tertiary referral center in China were included and followed‐up for 38,726.55 patient‐years, including those with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), systemic scleroderma (SSc), and idiopathic inflammatory myositis (IIM). Demographic data, cancer incidence, predilecting sites and cancer onset time were recorded and compared among the five AIDs. Results Four hundred and thirty (5.3%) patients developed cancer. Their median age was 57.5 years and AID duration was 79.8 months. The estimated total standardized incidence ratio (SIR) of cancer in AIDs patients was 3.37, with the highest SIR observed in IIM (4.31), followed by RA (3.99), SSc (3.77), SS (2.88) and SLE (2.58). The increased SIR of cancers in AID patients showed a female predominance (female vs. male: 3.59 vs. 2.77) and younger patient involvement (age <50 vs. ≥50 years: 4.88 vs. 3.04). Patients with SLE had increased SIRs for developing hematologic malignancies and solid tumors located in the urinary bladder, corpus uteri and cervix uteri. Patients with SS had a significantly high SIR for developing non‐Hodgkin's lymphoma. Within 3 years of IIM diagnosis, 74.6% of the patients developed cancer and they had a high risk of ovarian cancer. RA was associated with a wide distribution of scancers, including non‐Hodgkin's lymphoma, gynecologic, urinary tract, thyroid gland and lung cancers. SSc patients had increased SIRs for developing cervical uterine, lung, and breast cancers. Conclusion Patients with five major AIDs in China had an increased risk of developing cancer, with a predominance in women and younger patients, although cancer incidence, predilection sites and cancer onset time may vary greatly in each AID entity. |
| Author | Wen Zhang Ziyue Zhou Hua Chen Yunyun Fei Yan Zhao Xiaofeng Zeng Xuan Zhang Jingya Zhou Fengchun Zhang Mengtao Li Yiying Yang Huaxia Yang Lidan Zhao Huazhen Liu |
| AuthorAffiliation | 5 Department of Rheumatology National Center of Gerontology Institute of Geriatric Medicine Beijing Hospital Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China 2 Clinical Immunology Center Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China 1 Department of Rheumatology and Clinical Immunology National Clinical Research Center for Dermatologic and Immunologic Diseases the Ministry of Education Key Laboratory Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China 3 Department of Medical Records Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China 4 State Key Laboratory of Difficult, Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical Colle |
| AuthorAffiliation_xml | – name: 1 Department of Rheumatology and Clinical Immunology National Clinical Research Center for Dermatologic and Immunologic Diseases the Ministry of Education Key Laboratory Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China – name: 4 State Key Laboratory of Difficult, Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China – name: 2 Clinical Immunology Center Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China – name: 3 Department of Medical Records Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China – name: 5 Department of Rheumatology National Center of Gerontology Institute of Geriatric Medicine Beijing Hospital Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100730 P. R. China |
| Author_xml | – sequence: 1 givenname: Ziyue orcidid: 0000-0002-6580-4419 surname: Zhou fullname: Zhou, Ziyue organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 2 givenname: Huazhen surname: Liu fullname: Liu, Huazhen organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 3 givenname: Yiying surname: Yang fullname: Yang, Yiying organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 4 givenname: Jingya surname: Zhou fullname: Zhou, Jingya organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 5 givenname: Lidan surname: Zhao fullname: Zhao, Lidan organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 6 givenname: Hua surname: Chen fullname: Chen, Hua organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 7 givenname: Yunyun surname: Fei fullname: Fei, Yunyun organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 8 givenname: Wen surname: Zhang fullname: Zhang, Wen organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 9 givenname: Mengtao surname: Li fullname: Li, Mengtao organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 10 givenname: Yan surname: Zhao fullname: Zhao, Yan organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 11 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 12 givenname: Fengchun surname: Zhang fullname: Zhang, Fengchun organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 13 givenname: Huaxia surname: Yang fullname: Yang, Huaxia email: yanghuaxia2013@163.com organization: Chinese Academy of Medical Sciences and Peking Union Medical College – sequence: 14 givenname: Xuan surname: Zhang fullname: Zhang, Xuan email: zxpumch2003@sina.com organization: Chinese Academy of Medical Sciences and Peking Union Medical College |
| BackLink | https://cir.nii.ac.jp/crid/1870020693288475776$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/35357093$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1qFDEUxwep2Fp74wNIQC9E2JqPSSbjhVAWPwoFb_Y-ZJKT3awzyZrMVPZKH8Fn9EnMdrvSFvEmCcnv_-OQc55WRyEGqKrnBJ8TjOlbow09J5RK9qg6oZyyGeO1PLpzPq7Ocl5jjEkr25qzJ9Ux44w3uGUn1Y_FCpDz14AGvY4J6WmMfhimAMj6DDpDRj6YtDuhsbDJ568oOmR0MJDeIdh4C4OPfVx6o3tk9aiRS3FAGvU6LeH3z1-5PAAycRXTiPI42W1xovnKB_2seux0n-Hsdj-tFh8_LOafZ1dfPl3OL65mRjSCzVpijcG15bztuOi4FcRSZi0jVmBJOsEtxi1IhiUn3AFIyk2J1I7XIBw7rS73Whv1Wm2SH3Taqqi9urmIaal0Gr3pQbUUM2isNbxr6q5xXe2cJLqp285Zo6G43u9dm6kbwBoIY9L9Pen9l-BXahmvVUuIxJwXwetbQYrfJsijGnw20Pc6QJyyoqLmkpdeiYK-fICu45RC-alCCcEoL75Cvbhb0d9SDm0uAN4DJsWcEzhl_KhHH3cF-l4RrHbDpHbDpG6GqUTePIgcrP-EyR7-7nvY_odU84s5PWRe7TPB-1LObiWyKTgWLaNS1g1vSuv_ALE85W8 |
| CitedBy_id | crossref_primary_10_1016_j_autrev_2025_103779 crossref_primary_10_3390_ijms251810180 crossref_primary_10_1136_jitc_2023_007959 crossref_primary_10_1186_s40001_024_01967_5 crossref_primary_10_3389_fmolb_2023_1314753 crossref_primary_10_1016_j_revmed_2024_11_001 crossref_primary_10_1097_RHU_0000000000002122 crossref_primary_10_1007_s15012_025_8696_5 crossref_primary_10_1136_lupus_2024_001153 crossref_primary_10_1186_s13075_023_03157_w crossref_primary_10_3390_jcm13020415 crossref_primary_10_3389_fendo_2024_1401458 crossref_primary_10_3892_mco_2025_2833 crossref_primary_10_1016_j_canep_2023_102411 crossref_primary_10_1371_journal_pone_0298271 crossref_primary_10_1186_s41927_025_00477_z crossref_primary_10_1007_s00432_024_05885_1 crossref_primary_10_1097_CM9_0000000000002555 crossref_primary_10_1111_1759_7714_14849 crossref_primary_10_1111_imr_13378 crossref_primary_10_3389_fonc_2024_1322598 crossref_primary_10_1007_s00296_023_05386_3 crossref_primary_10_1007_s15015_024_3900_8 crossref_primary_10_2147_IJGM_S448720 crossref_primary_10_1111_1756_185X_15284 crossref_primary_10_1002_hed_27518 crossref_primary_10_1016_j_semarthrit_2023_152284 crossref_primary_10_3892_ol_2023_13669 crossref_primary_10_1007_s12672_024_01218_3 crossref_primary_10_1186_s12951_025_03308_y crossref_primary_10_1093_rheumatology_keae627 crossref_primary_10_1016_j_humimm_2023_110738 crossref_primary_10_7717_peerj_18650 crossref_primary_10_1016_j_jtauto_2024_100236 crossref_primary_10_3389_fonc_2023_1199195 crossref_primary_10_3390_rheumato4040017 crossref_primary_10_56543_aaeeu_2024_3_4_03 crossref_primary_10_1097_RHU_0000000000002075 crossref_primary_10_1016_j_heliyon_2024_e27413 crossref_primary_10_3390_genes14101844 crossref_primary_10_1371_journal_pone_0317369 crossref_primary_10_1016_j_jaut_2024_103231 crossref_primary_10_1097_LGT_0000000000000866 crossref_primary_10_1111_1756_185X_15095 crossref_primary_10_3389_fonc_2025_1440105 crossref_primary_10_1111_1756_185X_70059 crossref_primary_10_3389_fimmu_2024_1300457 |
| Cites_doi | 10.1007/s10067-014-2748-2 10.1093/rheumatology/kep404 10.1016/j.jncc.2022.02.002 10.1016/0002-9343(85)90245-1 10.3390/cancers13081886 10.1002/cac2.12197 10.1007/s00432-015-2032-0 10.1097/BOR.0000000000000535 10.1002/art.40895 10.1016/S0140-6736(00)03540-6 10.1016/S0140-6736(18)32335-3 10.1186/s13075-015-0728-9 10.1016/j.canlet.2017.04.024 10.1007/s10067-017-3676-8 10.3899/jrheum.140533 10.1177/0961203313520060 10.1002/art.1780400928 10.1056/NEJM197502132920706 10.3899/jrheum.140566 10.3322/caac.21338 10.1093/rheumatology/kes303 10.1002/art.40528 10.1016/j.juro.2012.12.014 10.1093/rheumatology/kes073 10.1002/art.21675 10.1136/ard.2008.091025 10.1111/j.1541-0420.2011.01616.x 10.1002/acr.21591 10.1177/0961203319857132 10.1186/ar2404 10.1097/MD.0000000000003540 10.1136/ard.60.5.433 10.1186/s13075-018-1760-3 10.1136/ard.61.6.554 10.1002/ijc.24141 10.1038/nrrheum.2011.62 10.1016/j.autrev.2014.03.001 10.1093/rheumatology/kex413 10.1002/art.27584 10.1016/j.autrev.2009.07.004 10.1093/jnci/87.7.524 10.1002/art.1780310302 10.1007/s00296-014-2982-6 10.1002/art.34473 10.1126/science.1246886 10.1016/j.ejmech.2018.09.027 10.1002/art.1780400424 10.1002/acr.22751 10.1097/BOR.0000000000000202 10.1002/art.30483 10.1136/annrheumdis-2013-204424 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. – notice: 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. – notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | RYH 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/cac2.12283 |
| DatabaseName | CiNii Complete Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | ZHOU et al |
| EISSN | 2523-3548 |
| EndPage | 446 |
| ExternalDocumentID | oai_doaj_org_article_9203e7ddc5b74b7fb4ff81a749bfdcae PMC9118055 35357093 10_1002_cac2_12283 CAC212283 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | 1OC 24P 7RV 7X7 88E 8FI 8FJ ABUWG ACCMX ACXQS ADKYN ADPDF ADZMN ADZOD AFKRA ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AVUZU AZQEC BENPR BMC C6C CCPQU EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW ITC K9- M0R M1P M~E NAPCQ OVD OVEED PHGZM PHGZT PIMPY PSQYO RPM RYH SOJ TEORI UKHRP 0R~ ACRMQ ADUKV AHSBF C24 EJD OK1 ROL RSV WIN AAYXX CITATION CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c6763-91dcc04d559b56b5d61d23dd31d6081b65d009e8308515fee825cdcc4f54e6f3 |
| IEDL.DBID | 24P |
| ISSN | 2523-3548 |
| IngestDate | Wed Aug 27 01:29:19 EDT 2025 Thu Aug 21 14:10:43 EDT 2025 Mon Jul 21 11:17:48 EDT 2025 Wed Aug 13 08:02:23 EDT 2025 Mon Jul 21 06:03:47 EDT 2025 Tue Jul 01 02:29:16 EDT 2025 Thu Apr 24 23:11:56 EDT 2025 Wed Jan 22 16:25:07 EST 2025 Thu Jun 26 22:38:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | epidemiology Sjögren's syndrome lupus erythematosus standardized incidence ratio cancer risk idiopathic inflammatory myositis autoimmune disease rheumatoid arthritis systemic scleroderma |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6763-91dcc04d559b56b5d61d23dd31d6081b65d009e8308515fee825cdcc4f54e6f3 |
| Notes | These authors contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1096-7851 0000-0001-6811-0255 0000-0001-8775-1699 0000-0002-6580-4419 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcac2.12283 |
| PMID | 35357093 |
| PQID | 2666325553 |
| PQPubID | 2040150 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9203e7ddc5b74b7fb4ff81a749bfdcae pubmedcentral_primary_oai_pubmedcentral_nih_gov_9118055 proquest_miscellaneous_2645858946 proquest_journals_2666325553 pubmed_primary_35357093 crossref_citationtrail_10_1002_cac2_12283 crossref_primary_10_1002_cac2_12283 wiley_primary_10_1002_cac2_12283_CAC212283 nii_cinii_1870020693288475776 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2022 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: May 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Cancer Communications |
| PublicationTitleAlternate | Cancer Commun (Lond) |
| PublicationYear | 2022 |
| Publisher | Wiley John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2015; 34 1997; 40 1988; 31 2016; 142 2014; 23 2010; 62 2012; 51 2001; 60 2015; 42 2013; 52 2018; 70 2019; 28 2011; 63 2009; 124 2014; 13 2018; 30 2011; 67 2018; 77 2021; 41 2017; 401 2012; 64 2018; 37 2010; 9 2009; 68 2015; 17 2019; 71 2006; 54 1980; 23 2013; 189 1975; 292 2016; 95 2008; 10 2018; 20 2011; 7 2021; 13 2010; 49 2015; 27 2018; 392 2022 2002; 61 2013; 72 1995; 87 2018; 158 2016 1985; 78 2001; 357 2014; 34 2018; 16 2016; 68 2014; 343 2018; 57 2016; 66 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_56_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_54_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_18_1 Liu Y (e_1_2_9_44_1) 2018; 16 e_1_2_9_41_1 e_1_2_9_20_1 e_1_2_9_45_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_30_1 e_1_2_9_53_1 Preliminary criteria for the classification of systemic sclerosis (scleroderma) (e_1_2_9_22_1) 1980; 23 e_1_2_9_51_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_40_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_23_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 Igusa T (e_1_2_9_58_1) 2018; 77 e_1_2_9_9_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_29_1 |
| References_xml | – volume: 20 start-page: 270 issue: 1 year: 2018 article-title: The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta‐analysis publication-title: Arthritis Res Ther – volume: 42 start-page: 282 issue: 2 year: 2015 end-page: 91 article-title: Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study publication-title: J Rheumatol – volume: 49 start-page: 571 issue: 3 year: 2010 end-page: 7 article-title: Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort publication-title: Rheumatology (Oxford) – volume: 60 start-page: 433 issue: 5 year: 2001 end-page: 41 article-title: Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies publication-title: Ann Rheum Dis – volume: 292 start-page: 344 issue: 7 year: 1975 end-page: 7 article-title: Polymyositis and dermatomyositis (first of two parts) publication-title: N Engl J Med – volume: 158 start-page: 502 year: 2018 end-page: 16 article-title: Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review publication-title: Eur J Med Chem – volume: 31 start-page: 315 issue: 3 year: 1988 end-page: 24 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum – volume: 189 start-page: 2262 issue: 6 year: 2013 end-page: 8 article-title: Autoimmune disease and subsequent urological cancer publication-title: J Urol – volume: 51 start-page: 1508 issue: 8 year: 2012 end-page: 13 article-title: Clinical features of anti‐TIF1‐alpha antibody‐positive dermatomyositis patients are closely associated with coexistent dermatomyositis‐specific autoantibodies and anti‐TIF1‐gamma or anti‐Mi‐2 autoantibodies publication-title: Rheumatology (Oxford) – volume: 13 start-page: 1886 issue: 8 year: 2021 article-title: Prevalence of Nasopharyngeal Carcinoma in Patients with Dermatomyositis: A Systematic Review and Meta‐Analysis publication-title: Cancers – volume: 68 start-page: 1136 issue: 7 year: 2009 end-page: 45 article-title: The safety of anti‐tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure‐adjusted pooled analyses of serious adverse events publication-title: Ann Rheum Dis – volume: 357 start-page: 96 issue: 9250 year: 2001 end-page: 100 article-title: Frequency of specific cancer types in dermatomyositis and polymyositis: a population‐based study publication-title: Lancet – volume: 42 start-page: 564 issue: 4 year: 2015 end-page: 71 article-title: Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population publication-title: J Rheumatol – year: 2022 article-title: Cancer incidence and mortality in China, 2016 publication-title: J Natl Cancer Center – volume: 142 start-page: 253 issue: 1 year: 2016 end-page: 62 article-title: Systemic lupus erythematosus and malignancies risk publication-title: J Cancer Res Clin Oncol – volume: 87 start-page: 524 issue: 7 year: 1995 end-page: 30 article-title: Bladder and kidney cancer following cyclophosphamide therapy for non‐Hodgkin's lymphoma publication-title: J Natl Cancer Inst – volume: 23 start-page: 581 issue: 5 year: 1980 end-page: 90 article-title: Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee publication-title: Arthritis Rheum – volume: 67 start-page: 678 issue: 2 year: 2011 end-page: 9 article-title: ggplot2: Elegant Graphics for Data Analysis by WICKHAM publication-title: H. Biometrics. – volume: 41 start-page: 1037 issue: 10 year: 2021 end-page: 48 article-title: Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 publication-title: Cancer Commun (Lond) – volume: 343 start-page: 152 issue: 6167 year: 2014 end-page: 7 article-title: Association of the autoimmune disease scleroderma with an immunologic response to cancer publication-title: Science – volume: 7 start-page: 360 issue: 6 year: 2011 end-page: 8 article-title: Susceptibility of patients with rheumatic diseases to B‐cell non‐Hodgkin lymphoma publication-title: Nat Rev Rheumatol – volume: 124 start-page: 1497 issue: 7 year: 2009 end-page: 502 article-title: Autoimmunity and lymphomagenesis publication-title: International Journal of Cancer – volume: 13 start-page: 730 issue: 7 year: 2014 end-page: 5 article-title: Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta‐analysis of the literature publication-title: Autoimmun Rev – volume: 57 start-page: 388 issue: 2 year: 2018 end-page: 96 article-title: Tumour TIF1 mutations and loss of heterozygosity related to cancer‐associated myositis publication-title: Rheumatology (Oxford) – volume: 40 start-page: 1725 issue: 9 year: 1997 article-title: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 66 start-page: 115 issue: 2 year: 2016 end-page: 32 article-title: Cancer statistics in China, 2015 publication-title: CA Cancer J Clin – volume: 54 start-page: 692 issue: 3 year: 2006 end-page: 701 article-title: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis publication-title: Arthritis Rheum – volume: 70 start-page: 1481 issue: 9 year: 2018 end-page: 8 article-title: Ectopic Germinal Center‐Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome publication-title: Arthritis Rheumatol – volume: 64 start-page: 2677 issue: 8 year: 2012 end-page: 86 article-title: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 64 start-page: 475 issue: 4 year: 2012 end-page: 87 article-title: American College of Rheumatology classification criteria for Sjögren's syndrome: a data‐driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort publication-title: Arthritis Care Res (Hoboken) – volume: 37 start-page: 81 issue: 1 year: 2018 end-page: 5 article-title: Malignancy as a comorbidity in rheumatic diseases: a retrospective hospital‐based study publication-title: Clin Rheumatol – volume: 401 start-page: 63 year: 2017 end-page: 71 article-title: Cancer incidence and mortality in China, 2013 publication-title: Cancer Lett – volume: 40 start-page: 761 issue: 4 year: 1997 end-page: 8 article-title: Non‐Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus publication-title: Arthritis Rheum – volume: 392 start-page: 1859 issue: 10159 year: 2018 end-page: 922 article-title: Global, regional, and national disability‐adjusted life‐years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017 publication-title: Lancet – volume: 77 start-page: 1179 issue: 8 year: 2018 end-page: 86 article-title: Autoantibodies and scleroderma phenotype define subgroups at high‐risk and low‐risk for cancer publication-title: Ann Rheum Dis – volume: 10 start-page: R45 issue: 2 year: 2008 article-title: A meta‐analysis of the incidence of malignancy in adult patients with rheumatoid arthritis publication-title: Arthritis Res Ther – volume: 68 start-page: 819 issue: 6 year: 2016 end-page: 27 article-title: Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999‐2012 publication-title: Arthritis Care Res (Hoboken) – volume: 27 start-page: 454 issue: 5 year: 2015 end-page: 60 article-title: Malignancies in systemic lupus erythematosus: a 2015 update publication-title: Curr Opin Rheumatol – volume: 61 start-page: 554 issue: 6 year: 2002 end-page: 8 article-title: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American‐European Consensus Group publication-title: Ann Rheum Dis – volume: 34 start-page: 1379 issue: 10 year: 2014 end-page: 86 article-title: No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan publication-title: Rheumatol Int – year: 2016 – volume: 95 issue: 18 year: 2016 article-title: Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population‐Based Dynamic Cohort Study in Taiwan publication-title: Medicine (Baltimore) – volume: 52 start-page: 143 issue: 1 year: 2013 end-page: 54 article-title: Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta‐analysis of observational studies publication-title: Rheumatology (Oxford) – volume: 28 start-page: 923 issue: 8 year: 2019 end-page: 36 article-title: Prognostic markers of lymphoma development in primary Sjögren syndrome publication-title: Lupus – volume: 16 start-page: 5960 issue: 5 year: 2018 end-page: 8 article-title: Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China publication-title: Oncol Lett – volume: 23 start-page: 284 issue: 3 year: 2014 end-page: 92 article-title: Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta‐analysis publication-title: Lupus – volume: 9 start-page: 195 issue: 4 year: 2010 end-page: 9 article-title: Malignancies in systemic lupus erythematosus publication-title: Autoimmun Rev – volume: 78 start-page: 44 issue: 1a year: 1985 end-page: 9 article-title: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment publication-title: Am J Med – volume: 63 start-page: 3032 issue: 10 year: 2011 end-page: 7 article-title: High incidence of potentially virus‐induced malignancies in systemic lupus erythematosus: a long‐term followup study in a Danish cohort publication-title: Arthritis Rheum – volume: 34 start-page: 273 issue: 2 year: 2015 end-page: 8 article-title: General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single‐center retrospective study publication-title: Clin Rheumatol – volume: 30 start-page: 630 issue: 6 year: 2018 end-page: 6 article-title: Pinal‐Fernández I. The diagnostic work‐up of cancer‐associated myositis publication-title: Curr Opin Rheumatol – volume: 62 start-page: 2569 issue: 9 year: 2010 end-page: 81 article-title: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Arthritis Rheum – volume: 72 start-page: 1747 issue: 11 year: 2013 end-page: 55 article-title: 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative publication-title: Ann Rheum Dis – volume: 17 start-page: 212 year: 2015 article-title: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta‐analysis publication-title: Arthritis Res Ther – volume: 71 start-page: 1360 issue: 8 year: 2019 end-page: 70 article-title: The IgG2 Isotype of Anti‐Transcription Intermediary Factor 1gamma Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis publication-title: Arthritis & Rheumatology – ident: e_1_2_9_38_1 doi: 10.1007/s10067-014-2748-2 – ident: e_1_2_9_56_1 doi: 10.1093/rheumatology/kep404 – ident: e_1_2_9_27_1 doi: 10.1016/j.jncc.2022.02.002 – ident: e_1_2_9_42_1 doi: 10.1016/0002-9343(85)90245-1 – ident: e_1_2_9_45_1 doi: 10.3390/cancers13081886 – ident: e_1_2_9_31_1 doi: 10.1002/cac2.12197 – ident: e_1_2_9_48_1 doi: 10.1007/s00432-015-2032-0 – ident: e_1_2_9_7_1 doi: 10.1097/BOR.0000000000000535 – ident: e_1_2_9_46_1 doi: 10.1002/art.40895 – ident: e_1_2_9_6_1 doi: 10.1016/S0140-6736(00)03540-6 – ident: e_1_2_9_2_1 doi: 10.1016/S0140-6736(18)32335-3 – ident: e_1_2_9_36_1 doi: 10.1186/s13075-015-0728-9 – ident: e_1_2_9_25_1 doi: 10.1016/j.canlet.2017.04.024 – ident: e_1_2_9_32_1 doi: 10.1007/s10067-017-3676-8 – ident: e_1_2_9_13_1 doi: 10.3899/jrheum.140533 – ident: e_1_2_9_24_1 – ident: e_1_2_9_49_1 doi: 10.1177/0961203313520060 – ident: e_1_2_9_15_1 doi: 10.1002/art.1780400928 – ident: e_1_2_9_21_1 doi: 10.1056/NEJM197502132920706 – ident: e_1_2_9_35_1 doi: 10.3899/jrheum.140566 – ident: e_1_2_9_26_1 doi: 10.3322/caac.21338 – ident: e_1_2_9_8_1 doi: 10.1093/rheumatology/kes303 – ident: e_1_2_9_5_1 doi: 10.1002/art.40528 – ident: e_1_2_9_53_1 doi: 10.1016/j.juro.2012.12.014 – ident: e_1_2_9_9_1 doi: 10.1093/rheumatology/kes073 – ident: e_1_2_9_41_1 doi: 10.1002/art.21675 – ident: e_1_2_9_14_1 doi: 10.1136/ard.2008.091025 – ident: e_1_2_9_30_1 doi: 10.1111/j.1541-0420.2011.01616.x – ident: e_1_2_9_20_1 doi: 10.1002/acr.21591 – ident: e_1_2_9_55_1 doi: 10.1177/0961203319857132 – ident: e_1_2_9_28_1 – ident: e_1_2_9_12_1 doi: 10.1186/ar2404 – ident: e_1_2_9_33_1 doi: 10.1097/MD.0000000000003540 – ident: e_1_2_9_39_1 doi: 10.1136/ard.60.5.433 – ident: e_1_2_9_47_1 doi: 10.1186/s13075-018-1760-3 – ident: e_1_2_9_19_1 doi: 10.1136/ard.61.6.554 – ident: e_1_2_9_3_1 doi: 10.1002/ijc.24141 – volume: 23 start-page: 581 issue: 5 year: 1980 ident: e_1_2_9_22_1 article-title: Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee publication-title: Arthritis Rheum – ident: e_1_2_9_4_1 doi: 10.1038/nrrheum.2011.62 – ident: e_1_2_9_37_1 doi: 10.1016/j.autrev.2014.03.001 – ident: e_1_2_9_10_1 doi: 10.1093/rheumatology/kex413 – ident: e_1_2_9_18_1 doi: 10.1002/art.27584 – ident: e_1_2_9_34_1 doi: 10.1016/j.autrev.2009.07.004 – ident: e_1_2_9_43_1 doi: 10.1093/jnci/87.7.524 – ident: e_1_2_9_17_1 doi: 10.1002/art.1780310302 – ident: e_1_2_9_11_1 doi: 10.1007/s00296-014-2982-6 – ident: e_1_2_9_16_1 doi: 10.1002/art.34473 – ident: e_1_2_9_40_1 doi: 10.1126/science.1246886 – ident: e_1_2_9_57_1 doi: 10.1016/j.ejmech.2018.09.027 – ident: e_1_2_9_54_1 doi: 10.1002/art.1780400424 – volume: 77 start-page: 1179 issue: 8 year: 2018 ident: e_1_2_9_58_1 article-title: Autoantibodies and scleroderma phenotype define subgroups at high‐risk and low‐risk for cancer publication-title: Ann Rheum Dis – ident: e_1_2_9_50_1 doi: 10.1002/acr.22751 – ident: e_1_2_9_51_1 doi: 10.1097/BOR.0000000000000202 – ident: e_1_2_9_52_1 doi: 10.1002/art.30483 – volume: 16 start-page: 5960 issue: 5 year: 2018 ident: e_1_2_9_44_1 article-title: Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China publication-title: Oncol Lett – ident: e_1_2_9_23_1 doi: 10.1136/annrheumdis-2013-204424 – ident: e_1_2_9_29_1 |
| SSID | ssj0001989453 ssib048324904 |
| Score | 2.423166 |
| Snippet | Background
Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases... Cancer incidence and mortality have received critical attention during the long-term management of morbidities in patients with autoimmune diseases (AIDs).... BackgroundCancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune diseases... Abstract Background Cancer incidence and mortality have received critical attention during the long‐term management of morbidities in patients with autoimmune... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 435 |
| SubjectTerms | Acquired Immunodeficiency Syndrome Acquired Immunodeficiency Syndrome - complications Age Arthritis, Rheumatoid Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - epidemiology autoimmune disease Autoimmune Diseases Autoimmune Diseases - complications Autoimmune Diseases - epidemiology Blood cancer Breast cancer Cancer cancer risk Classification Cohort analysis Cohort Studies Confidence intervals Demographics Disease epidemiology Female Gender Hospitals Humans idiopathic inflammatory myositis Inflammatory diseases Lung cancer Lupus lupus erythematosus Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - epidemiology Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin - complications Male Medical diagnosis Middle Aged Musculoskeletal diseases Neoplasms Neoplasms - complications Neoplasms - epidemiology Neoplasms. Tumors. Oncology. Including cancer and carcinogens Original Original Articles Ovarian cancer Patients Population RC254-282 Rheumatism Rheumatoid arthritis Rheumatology RNA polymerase Scleroderma Sjogren's Syndrome Sjogren's Syndrome - complications Sjogren's Syndrome - epidemiology Sjögren's syndrome standardized incidence ratio systemic scleroderma Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9ZAEF6kp15EsWq0lRG9KMQm2a-kt_bFUgQ9Vegt7CdGaiLvx1l_gr_RX-LMJo3vi0UvXkLIbsJmZ3bmmWT2GcZeViG4plYhb0QTc1Fak1NRdzx4Z5WtnTW03_n9B3XxUby7kldbpb4oJ2ykBx4n7ripCh60905aLayOVsRYl0aLxkbvTCDriz5vK5hKX1eIV1zymY-0OnbGVW9KInvZ8UCJqB_9St91t2HMP1MltyFs8kHn99jdCTzC6Tjo--xO6B-wbyhpiGi04Iv5PCzBbNZDR7s-Akx_X1bQ9QQOVwEQ7gFlk8MQwZHAlycQfheJJYkBJY0CbTsBA9eUKP7z-48VNgSgarrLNSRKWnwmpOLbB-zy_O3l4iKfyirkTqE1QfPmnSuEx1jCSmWlV6WvuPe89AoBglXSI_AKNSc0JmMIGEQ6vEVEKYKK_CHb64c-PGbguULX5rw0TSFMU9VeK4MBnPC2NmVhMvbqZqZbN1GOU-WL63YkS65akkqbpJKxF3PfryPRxq29zkhgcw8ix04XUGXaSWXaf6lMxo5Q3DgiOpZosBAyK8SxNXpqqbXK2OGNIrTTil61CGQUx_hL4hiez824FukHi-nDsKE-AqMv1Dx8xKNRb-aRcsmlLhq8W-9o1M6r7Lb03afE990QTZ-UGXuddO8v09MuThdVOnvyPybqKduvaLdHyu88ZHvr5SYcIQZb22dpuf0C1iMxDg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXLigVrwCLTKCC0ihSfxKekFl1apCglOR9hb5CalKUpLdc_kJ_EZ-CTPebLYrql6iKLajxDOe-WyPvyHkbeG9rUrp04pXIeW50SkmdYeLs0aa0hqN552_fJVn3_jnuZiPC27DGFa5tonRULvO4hr5ITgSyQD_Cvbx6leKWaNwd3VMoXGfPEDqMgzpUnO1WWNBdnHBJlbS4tBqW3zIkfJlyw9Fun7wLm3T3IY0_w-YvAlkoyc63SWPRghJj1cy3yP3fPuYXIO8aQDTRX_qi66nernoGjz74em4BzPQpkWIOHgKoI9iTDntArUo9v6I-k2qWJQbxdBRiodPqKaXGC7-9_efAQo8xZy6_YJGYlp4J40puJ-Q89OT89lZOiZXSK0EmwJGzlmbcQczCiOkEU7mrmDOsdxJgAlGCgfwy5cMMZkI3sNU0kITHgT3MrCnZKftWv-cUMckODjrhK4yrquidEpqmMZxZ0qdZzoh79Y9XduReBzzX1zWK8rkokap1FEqCXkz1b1a0W3cWusTCmyqgRTZ8UHXf6_HEVdXRca8cs4Ko7hRwfAQylwrXpngrPYJOQBxwxfhNQezBcBZApotwV8LpWRC9teKUI_jeqg3WpiQ11MxjEjcZtGt75ZYh8McDDQPXvFspTfTlzLBhMoqaK22NGrrV7ZL2uZHZP2ukKxPiIS8j7p3R_fUs-NZEe9e3P0PL8nDAk9zxPjNfbKz6Jf-ADDWwryKA-kfZrYmiQ priority: 102 providerName: ProQuest |
| Title | The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large‐scale cohort study in China |
| URI | https://cir.nii.ac.jp/crid/1870020693288475776 https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcac2.12283 https://www.ncbi.nlm.nih.gov/pubmed/35357093 https://www.proquest.com/docview/2666325553 https://www.proquest.com/docview/2645858946 https://pubmed.ncbi.nlm.nih.gov/PMC9118055 https://doaj.org/article/9203e7ddc5b74b7fb4ff81a749bfdcae |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKe-GCQLwW2pURXEAKTRw_EsSlXbaqkCgVKmhvkV8pQSVBye4ZfgK_kV_CjJPNsqJC4mIlazvyZmbsbxzPN4Q8Y97bPJM-ynleRjwxOsKk7lA4a6TJrNEY7_zuTJ5-5G8XYrFDXq9jYXp-iHHDDS0jzNdo4Np0hxvSUKste5kge8sNsoextcicz_j5ZocFucUDDSUDbytKAZuP_KTscNN9a0UKxP2wztRVdR3m_Pvo5J-QNqxJJ7fJrQFM0qNe-nfIjq_vku8geVrCJEa_6i9NS_Vq2VQYBeLp8DWmo1WNYLHzFOAfxdPltCmpRQVoX1G_SRqLEqR4iJRiGArV9AoPjv_68bODCk8xu267pIGiFp5JQzLue-TiZH4xO42GNAuRlTC7wHTnrI25A9_CCGmEk4ljqXNp4iQABiOFAyDmsxTRmSi9B6fSQhdeCu5lmd4nu3VT-4eEulTCUmed0HnMdc4yp6QGh447k-kk1hPyfP2mCztQkGMmjKuiJ09mBUqlCFKZkKdj22898ca1rY5RYGMLJMsOPzTtZTHYXpGzOPXKOSuM4kaVhpdllmjFc1M6q_2EHIC4YURYJjCBAYSWgGszWLmFUnJC9teKUAwW3hUAbGQK_piAMTwZq8E28YOLrn2zwjYcvDHQQnjEg15vxpGmIhUqzqG32tKorb-yXVNXnwP_d460fUJMyIuge_94PcXsaMbC1aP_afyY3GQY5RHOde6T3WW78geAvZZmGkwMSrVQU7J3PD87_zAN-xhw9_7TfP7mN2qtLcE |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9AAXBOJlaGERcADJ1PY-bCMh1IZWKW0jhILU22pfLkHFLnkIcYKfwB_hT_FLmNk4CRFVb71YUXa9sne-mfnWOztDyNPMe1sW0sclL6uYp0bHWNQdLs4aaQprNJ53PurL3kf-7lgcr5Hf87MwGFY5t4nBULvG4jfyLXAkkgH_FezN2dcYq0bh7uq8hMYMFgf--zdYso1f778F-T7Lsr3dQbcXt1UFYitBmUC7nbUJd0CljZBGOJm6jDnHUifBPxopHPAOXzAkI6LyHtZQFm7hleBeVgyGvULWOYOVTIes7-z2339YftTBdOaCLdKgZltW2-xlijlmVhxfqA8A7qweDs-jtv9HaP7LnIPr27tBrreclW7PQHaTrPn6FvkBAKMV2Er6RX9uRlRPJ80QD5t42m76jOmwRk469hRYJsUgdtpU1CLORq-oX9amRaBQjFWleNqFanqK8el_fv4aQ4OnWMR3NKEhEy6MSUPN79tkcBnzfod06qb29wh1TIJHtU7oMuG6zAqXSw3rRu5ModNER-T5fKaVbTOdY8GNUzXL0ZwplIoKUonIk0Xfs1l-j3N77aDAFj0wJ3f4oxmdqFbFVZklzOfOWWFybvLK8KoqUp3z0lTOah-RTRA3PBFeU7CTwNQl0OcCCILIcxmRjTkQVGtIxmoJ-4g8XjSDCcB9HV37Zop9OCz6AHkwxN0ZbhZPygQTeVLC3fkKolZeZbWlHn4KacZLzA4oREReBOxdMD2qu93Nwq_7F7_DI3K1Nzg6VIf7_YMH5FqGR0lC8OgG6UxGU78JBG9iHrZqRYm6ZEX-C3GNY7Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyEuCMQrtAUjuIAUmoftJIjLsrAqr4pDF1VcLD9LUJtU2d0z_AR-I7-EGW82y4oKiUsUxRPLyczY3yTjbwh5kjlnqlK4uGKVj1mqVYxF3eFgjRa6NFrhfuePR-Jwyt6d8JMt8nK1F2bJDzF8cEPPCPM1OviF9Qdr0lCjTPY8RfaWK2QHafLApndGn6dfputvLMguHogoM4i34hzQ-cBQmh2sO9hYkwJ1P6w0TV1fhjr_Tp78E9SGVWlyg1zv4SQdLfV_k2y55hb5DrqnHqYxeq6-tR1Vi3lb4z4QR_v_MTNaNwgXZ44CAKSYX05bTw2aQPeCunXZWNQhxTRSihtRqKJnmDr-68fPGTQ4ivV1uzkNJLXQJw3luG-T48mb4_Fh3BdaiI2A-QUmPGtMwixEF5oLza1IbZZbm6dWAGTQgluAYq7MEZ9x7xyElQZuYZ4zJ3x-h2w3bePuEWpzAYudsVxVCVNVVtpCKAjpmNWlShMVkaerNy1NT0KOtTDO5JI-OZOoFRm0EpHHg-zFknrjUqlXqLBBAumyw4W2O5W998kqS3JXWGu4LpguvGbel6kqWKW9NcpFZB_UDSPCYwpTGIBoAci2hLWbF4WIyN7KEGTv4zMJ0EbkEJFxGMOjoRm8E3-5qMa1C5RhEI-BFUIXd5d2M4w05zkvkgruLjYsauNRNlua-mtgAK-QuI_ziDwLtveP1yPHo3EWzu7_j_BDcvXT64n88Pbo_S65luGWj5DkuUe2593C7QMQm-sHvb_9BmWkLRk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+five+major+autoimmune+diseases+increase+the+risk+of+cancer%3A+epidemiological+data+from+a+large%E2%80%90scale+cohort+study+in+China&rft.jtitle=Cancer+communications+%28London%2C+England%29&rft.au=Zhou%2C+Ziyue&rft.au=Liu%2C+Huazhen&rft.au=Yang%2C+Yiying&rft.au=Zhou%2C+Jingya&rft.date=2022-05-01&rft.issn=2523-3548&rft.eissn=2523-3548&rft.volume=42&rft.issue=5&rft.spage=435&rft.epage=446&rft_id=info:doi/10.1002%2Fcac2.12283&rft.externalDBID=10.1002%252Fcac2.12283&rft.externalDocID=CAC212283 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2523-3548&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2523-3548&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2523-3548&client=summon |